We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals

2.86 USD
-0.03
1.04%
At close Updated Sep 16, 11:47 AM EDT
1 day
-1.04%
5 days
2.51%
1 month
7.52%
3 months
24.89%
6 months
-14.37%
Year to date
41.58%
1 year
132.52%
5 years
-82.32%
10 years
-85.77%
 

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Employees: 61

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 14.3%
Neutral 78.6%
Negative 7.1%
Neutral
GlobeNewsWire
5 days ago
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Neutral
Seeking Alpha
5 days ago
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Neutral
GlobeNewsWire
13 days ago
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
1 month ago
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
1 month ago
Acumen Pharmaceuticals Q2 Earnings Call Highlights
Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.
Acumen Pharmaceuticals Q2 Earnings Call Highlights
Neutral
GlobeNewsWire
1 month ago
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Neutral
GlobeNewsWire
1 month ago
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
Positive
Zacks Investment Research
1 month ago
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Negative
Zacks Investment Research
2 months ago
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Price charts implemented using Lightweight Charts™